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Aza heterocyclic compounds are an important class of organic compounds that 
play a major role in medicinal chemistry. Majority of the heterocyclic motifs such as 
imidazoles, triazoles, piperazines etc. act as building blocks for synthesizing active 
pharmaceutical ingredients. Several pharmaceutical drugs include these motifs due to 
their varying physicochemical properties, which enable them to exhibit wide range of 
pharmacological activities ranging from anti-fungal, anti-neoplastic, anti-helmintic, anti-
microbial etc. Owing to their electron rich ring system, imidazole and piperazine based 
motifs have become an attractive target for design and development of novel chemical 
structures as new drugs. In the current study, we have synthesized a series of 2, 4, 5-
trisubstituted imidazole-based compounds containing different pharmacophores using 
multicomponent coupling reactions such as Baylis-Hillman reaction and Debus-
Radziszewski reaction. A preliminary report on the structural activity relationship of the 
synthetic compounds was also obtained based on an in vitro cytotoxicity evaluation 
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 Heterocyclic structures are an important motif found in majority of 
pharmacologically active compounds and natural products. The effectiveness of these 
ring systems as potent pharmaceuticals relates to their ability to manipulate lipophilicity, 
hydrogen bonding capacity of molecules and polarity thus improving the 
pharmacological, pharmacokinetic, and toxicological properties of the drug candidates.1 
Heterocyclic azoles, imidazoles in particular exhibit multitude of biological activities and 
are accordingly present in a variety of pharmaceutical drugs. 
Multicomponent Coupling Reactions 
 Multi-component coupling reactions are particularly useful in pharmaceutical 
chemistry and are highly utilized in drug design and development.1,2  Reactions such as 
Passerini reaction,3-7 Ugi reaction,8 Baylis-Hillman reaction,9-16 click reaction, 17-20 etc. 
yield highly functionalized chemical structures and they are very highly employed in 
medicinal chemistry. For the past several years, our groups have been working on the 
development of novel small molecules using reactions such as Baylis-Hillman reaction, 
Passerini reaction, click reaction, aldol condensation, reductive amination, etc. for 
potential applications in drug discovery.21-33 
 Multicomponent coupling reactions (MCRs) are one pot synthesis reactions where 
two or more components react to form a final product of which all the atoms from each 
component contribute to the newly formed product.34 MCRs are convenient and simple 





 Debus-Radziszewski Reaction was first reported by Debus in 1858, fully 
developed by Radziszewski in 1882, and further modified by Weidenhagen in 1935. The 
Debus-Radziszewski synthesis is an organic reaction used for the synthesis of 2,4,5-
trisubstituted imidazoles from a dicarbonyl, an aldehyde and ammonia in acetic acid 
(Figure 1). The dicarbonyl component is generally glyoxal, but may also include several 
1,2-diketones and ketoaldehydes. The method is used commercially for producing several 
imidazoles and is an example of multi component reaction.35 
 
Figure 1. Debus-Radziszewski Reaction. 
Baylis-Hillman Reaction 
 Another MCR that has been used immensely in the synthesis of heterocyclic 
compounds is the Baylis-Hillman Reaction (Figure 2). The Baylis–Hillman reaction is a 
carbon-carbon bond forming reaction between the α-position of an activated alkene and 
an aldehyde. This reaction offers a densely functionalized product (e.g., functionalized 
allyl alcohol in the case of aldehyde as the electrophile). This coupling of an activated 
alkene derivative with an aldehyde is catalyzed by a tertiary amine (e.g.: DABCO = 1,4-
Diazabicyclo [2.2.2] octane).  BH reaction has numerous advantages as a valuable 
synthetic method. It is an atom-economic coupling of multiple components and the 

















activated alkene, (b) quenching the Zwitterion adduct with an electrophile, followed by 
(c) proton transfer and elimination of the catalyst. 
 
 
Figure 2. Baylis-Hillman Reaction. 
  
 This thesis will detail our efforts on the synthesis of novel azaheterocyclic motifs 
using these two reactions outlined above as the key steps.  We envisaged the synthesis of 
novel 2,4,5-trisubstituted imidazoles as well as their corresponding quaternary 
ammonium salts in an effort to increase their efficacy and solubility. We also performed 
preliminary biological evaluations of the synthesized compounds to determine their 












Preparation of Azaheterocyclic Compounds 
 Owing to the importance of 2,4,5-trisubstituted imidazoles, as well as the diverse 
functionalization possibilities that are possible using Baylis-Hillman and Debus-
Radziszewski reactions, we undertook a project involving the development of 
trisubstituted imidazoles as anticancer agents using these reactions as the key steps. We 
also planned to incorporate the groups such as N-methylpiperazine, N,N,N’-
trimethylethylenediamine, morpholine etc. on this template to enhance water solubility.  
The Baylis-Hillman motif was chosen to enhance the efficacy as this template is a potent 
Michael acceptor and could potentially bind to a variety of biological targets (Figure 3).   
 
 


















Synthesis of p-imidazolyl α-aminomethylcinnamates 
 In order to synthesize the corresponding final compounds, two different kinds of 
1,2 diketone moieties were utilized. Initial reactions were optimized using benzil as the 
starting material.  Once the conditions were optimized using benzil, we synthesized the 
corresponding para-fluoro substituted benzil derivative using a literature protocol.  We 
chose the fluoro derivative because of the ubiquitous nature of fluorine and its vast 
applications in medicinal chemistry.  
 The 1,2-diketone required for the Debus-Radziszewski reaction was synthesized 
from its corresponding aldehyde by reacting it with KCN in ethanol to get an α-
hydroxyketone which was further oxidized with copper (II) acetate, ammonium nitrate 
and 80% aqueous acetic acid to get the 1,2-diketone intermediate (Figure 4).  
 
Figure 4. Preparation of Fluoro substituted Benzil. 
 
 During initial efforts, a variety of reaction conditions were screened in order to 
optimize the reaction conditions. In the first series of experiments, using the Debus-
Radziszewski protocol, benzil (1,2-diketone) was coupled with terephthalaldehyde using 



















a trisubstituted imidazole aldehyde (Figure 5).  
 
Figure 5. Synthesis of trisubstituted imidazole aldehyde. 
  
 The aldehyde adduct was then coupled with methyl acrylate using DABCO as 
catalyst in acetonitrile using the Baylis Hillman protocol. Acetonitrile was chosen as the 
solvent as it has been reported to accelerate the Baylis Hillman reaction, however, much 
to our dismay, the reaction did not materialize in the formation of the product (Figure 6).  
We attempted several other conditions including heating the reaction, changing solvents, 
etc. and none of our efforts were successful and we recovered the starting material in all 
of these conditions. 
 






 Following the unsuccessful efforts to synthesize the 2,4,5-trisubstituted imidazole 
analogs using the above figures 5 & 6, we envisioned the synthesis of these compounds 
by switching the order of Baylis-Hillman and Debus-Radziszewski reactions. 
Accordingly, terephthalaldehyde was initially coupled with methyl acrylate using 
DABCO as catalyst in acetonitrile (Figure 7).  The coupling of the acrylate and aldehyde 
resulted in the formation of methyl 2-((4-formylphenyl) (hydroxy)methyl) acrylate and 
dimethyl 2,2'-(1,4-phenylenebis(hydroxymethylene))diacrylate as main products. In spite 
of our best efforts to optimize this reaction to form one adduct, we were unable to form 
one compound and a mixture of two products was invariably obtained (Figure 7). 
 
 
Figure 7. Baylis-Hillman reaction of terephthalaldehyde. 
 
 The mono-adduct, methyl 2-((4-formylphenyl) (hydroxy)methyl) acrylate 3 was 
purified using column chromatography and was used for further reactions.  In an attempt 
to synthesize the target compounds, the alcohol group on BH adduct was acetylated by 
acetic anhydride and DMAP using methylene chloride as solvent. The obtained 




catalyst in DMF to get the intermediate p-formyl α-aminomethylcinnamate 5 (Figure 8). 
 
 
Figure 8. Synthesis of p-formyl α-aminomethylcinnamate. 
 
 The p-formyl α-aminomethylcinnamate 5 was coupled with benzil 6 using the 
Debus-Radziszewski protocol under two different conditions to obtain the final target 
trisubstituted imidazole product 9. It was observed that the reaction of benzil and 
aldehyde 5 with ammonium acetate in the presence of acetic acid afforded better yields 
when compared to the reaction using sodium dihydrogen phosphate instead of acetic acid 





Figure 9. Preparation of p-imidazolyl α-aminomethylcinnamates. 
 
 In spite of our best efforts, we were not able to increase the yield of these 
reactions any further.  Accordingly, a second strategy was developed to further increase 
the yield of the final products. This involved the BH reaction of terephthalaldehyde and 
coupling the adduct 3 with 1,2-diketone to form trisubstituted imidazolyl-Baylis Hillman 
conjugates 7a-b. The conjugate was then acetylated and reacted with different secondary 
amines in the presence of K2CO3 and DMF to yield the final products 9a-p. The overall 
reaction scheme is presented below (Figure 10).  We employed amines such as imidazole, 
triazole, nitroimidazole, nitromethylimidazole, morpholine, pyrazine, and 
trimethylethylene diamine and the compounds prepared in this methodology are shown in 














Figure 11. p-imidazolyl α-aminomethylcinnamates. 
 
 




Synthesis of Quaternary Ammonium Salts 
 Considering the vast applications of quaternary ammonium salts in medicinal 
chemistry, we synthesized quaternary salts of select few target imidazoles by reacting 
them with methyl iodide, allyl bromide and methyl 2-(bromomethyl)acrylate. 
Quaternization was achieved by reacting the appropriate tertiary amine with the 
corresponding alkyl halide at room temperature (Figure 13). The reaction was successful 
under multiple solvent systems; however, the best results were obtained with 























































































































































 In order to identify the optimal conditions for the ammonium salt formation, 
different solvents were used and the results are shown in Table 1.  The reactions were 
carried out in three different solvents acetonitrile, ether, and tetrahydrofuran at different 
reaction time intervals. All the reactions were carried out at room temperature. When the 
reaction was carried out in the presence of acetonitrile for 6 hours and 18 hours, the 
percentage yield of the product was ~10% and ~20% respectively. Similar result was 
found when the reaction was carried out in the presence of ether for 7 hours, however an 
increase in the percentage yield of the product was observed when the reaction time was 
increased to 18 hours. The percentage yield was found to be doubled (40%) at 18 hours 
with ether. The best yields of the product were obtained when the reaction was carried 
out in the presence of tetrahydrofuran. The product yield was found to be 50% when the 
reaction was carried out for 5 hours and 95% after stirring for 16 hours. Based on the 
optimization, all the remaining salts were synthesized using tetrahydrofuran as solvent 
and the reaction was carried out for 16 hours. The product was precipitated out and was 
filtered.  All the quaternary salts were further purified by triturating with diethyl ether 

















1 CH3I CH3CN 6 RT ~ 10% 
2 CH3I CH3CN 18 RT ~ 20% 
3 CH3I Ether 7 RT ~20% 
4 CH3I Ether 18 RT ~ 40% 
5 CH3I THF 5 RT ~ 50% 






 The synthesized compounds 2,4,5 trisubstituted imidazoles 9a-p and their 
quaternary salts 10a-l were screened for in vitro cytotoxicity against skin cancer (SK-
MEL-5), breast cancer (MCF-7) and triple negative breast cancer (MDA-MB-231) cell 
lines. A protocol of 48 h continuous drug exposure was used, and a MTT cell 
proliferation assay was employed to estimate cell viability. The cell lines were grown in 
their respective media containing 10% fetal bovine serum and were seeded into 96-well 
microtiter plates in 200 μL aliquots at plating densities depending on the doubling time of 
individual cell lines. The microtiter plates were incubated at 37 ºC, 5% CO2, 95% air, and 
100% relative humidity for 24 h prior to addition of experimental drugs. Aliquots of 2 μL 
of the test compounds were added to the wells already containing 198 μL of cells, 
resulting in the required final concentrations of test compounds. For each compound, four 
concentrations (2.5, 5, 10 and 20 μM) were evaluated, and each was done in triplicate 
wells. Plates were incubated further for 48 h, and the experiment was terminated by the 
addition of 10 μL of 5% MTT and incubated further for 60 min at 37 ºC. Later, the 
plates1were washed and air-dried and bound stain was subsequently dissolved using 100 
μL of DMSO. The absorbance was monitored on a multimode plate reader at a 
wavelength of 570 nm. Percent growth was calculated on a plate-by-plate basis for test 
wells relative to control wells.  
 The IC50 (µM) values for the 2,4,5 trisubstituted imidazoles are shown in Tables 
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Table 5 
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 Based on the IC50 values for the various derivatives tested, we were able to 







Figure 15. Lead Derivatives 
 
Conclusions 
 In conclusion, we have been able to optimize the synthesis of trisubstituted 
imidazoles employing Baylis-Hillman and Debus-Radziszewski reactions as the key 
steps.  We were also able to obtain quaternary salts of these trisubstituted imidazoles 




their biological activity through cell viability assay.  All the synthesized trisubstituted 
imidazole derivatives as well as some of the intermediates were evaluated for their 
general cytotoxicity against human skin (SK-MEL-5), and human breast cancer (MCF-7 
& MDA-MB-231) cell lines. The preliminary biological evaluation of these molecules 
has shown some promise and we have been able to identify few leads for future 









Materials and Methods 
 All the reactants were of reagent grade, purchased from Acros Organics, Alfa 
Aesar or Sigma Aldrich, and used without further purification. All solvents were used 
without further drying or purification and were of ACS grade purchased from Fisher 
Scientific.  All operations were carried out under an inert atmosphere of nitrogen. 
Glassware for all reactions was oven dried at 125 °C and cooled under nitrogen prior to 
use. Liquid reagents and solvents were introduced by oven-dried syringes or cannulas 
through septa sealed flasks under a nitrogen atmosphere. 
Instrumentation 
 Nuclear Magnetic Spectroscopy (NMR) spectra were produced using a Varian 
400 MHz spectrophotometer. The instrument was maintained at 25o C operating at 400 
MHz for 1H NMR, and 101 MHz for 13C NMR. The deuterated solvent (CDCl3, DMSO-
d6) used for each respective spectrum is referenced to the appropriate literature peak shift. 
Procedures 
General procedure for Debus-Radziszewski Reaction. To a stirred solution of 
methyl 2-((4-formylphenyl)(hydroxy)methyl)acrylate (1 mmol) in acetic acid (10 mL), 
was added substituted benzil (0.8 mmol), followed by addition of NH4OAc (25 mmol) 
and refluxed for 10 h. Upon completion (TLC), then the pH was adjusted to 8 with 
saturated NaHCO3 to affect precipitation. The resulting solid was filtered and dried under 
vacuum to obtain pure methyl 2-((4-(4,5-diaryl-1H-imidazol-2-yl) phenyl) (hydroxy) 




dichloromethane (10 mL) at 0 °C, was added acetic anhydride (1.5 mmol), followed by 
addition of triethylamine (1.5 mmol) and DMAP (0.1 mmol). Upon completion 
(monitored by TLC), diluted with water and extracted with ethyl acetate (2 X 15 mL), the 
combined extracts were washed saturated NH4Cl, brine and dried over anhydrous 
Na2SO4. Concentrated the organic layer under vacuum and purified by silica gel column 
chromatography (hexanes: ethyl acetate) to obtain pure 2-(acetoxy(4-(4,5-diaryl-1H-
imidazol-2-yl)phenyl)methyl)acrylate (8a) as solids in 73-79% yield (over two steps). 





(8a): Pale yellow solid; mp: °C; 1H NMR (400 MHz, CDCl3): δ 7.80 (d, J = 8.0 Hz, 2H), 
7.53 – 7.37 (m, 4), 7.31 (d, J = 8.2 Hz, 2H), 7.28 – 7.16 (m, 6H), 6.66 (s, 1H), 6.38 (s, 
1H), 5.83 (s, 1H), 3.64 (s, 3H), 2.04 (s, 3H); 13C NMR (101 MHz, CDCl3): δ 169.8, 








methyl)acrylate (8b ): Yield: 81%; pale yellow solid; mp: °C; 1H NMR (400 MHz, 
DMSO-d6): δ 7.80 (d, J = 8.0 Hz, 2H), 7.53 – 7.37 (m, 4), 7.31 (d, J = 8.2 Hz, 2H), 7.28 – 
7.16 (m, 6H), 6.66 (s, 1H), 6.38 (s, 1H), 5.83 (s, 1H), 3.64 (s, 3H), 2.04 (s, 3H); 13C NMR 
(101 MHz, CDCl3): δ 169.8, 165.5, 145.8, 139.2, 137.7, 130.2, 128.4, 127.9, 127.3, 
126.4, 125.6, 72.9, 52.1, 21.0;   
General procedure for nucleophilic substitution. To a stirred solution of 
methyl 2-(acetoxy(4-(4,5-diaryl-1H-imidazol-2-yl)phenyl)methyl)acrylate (1 mmol), was 
added appropriate secondary amine (1.2 mmol), followed by  addition of K2CO3 (1.5 
mmol) at room temperature, and stirred for 10-12 h. Upon completion via thin layer 
chromatography, diluted with cold water to affect precipitation, filtered off solid and 







yl)phenyl)acrylate (9a ): Yield: 84%; pale yellow solid; mp: 223 – 225 °C; 1H NMR (400 
MHz, DMSO-d6): δ 12.82 (s, 1H), 8.14 (d, J = 7.6 Hz, 2H), 7.96 (s, 1H), 7.70 – 7.33 (m, 
10H), 7.34 – 7.15 (m, 3H), 7.02 (s, 1H), 6.87 (s, 1H), 5.05 (s, 2H), 3.74 (s, 3H); 13C NMR 
(101 MHz, DMSO-d6): δ 167.5, 145.3, 143.9, 138.3, 135.6, 133.8, 131.9, 131.5, 130.7, 
129.6, 129.4, 129.1, 128.9, 128.6, 127.8, 127.3, 127.2, 126.1, 53.1, 43.3. HRMS (ESI): 
m/z, calcd. for C29H25N4O2 [M+H]
+ 461.1972, found 461.1961. 
 
Methyl (E)-2-((1H-1,2,4-triazol-1-yl)methyl)-3-(4-(4,5-diphenyl-1H-imidazol-2-
yl)phenyl) acrylate (9b ): Yield: 82%; yellow solid; mp: 109 – 111 °C; 1H NMR (400 
MHz, DMSO-d6): δ 12.80 (s, 1H), 8.58 (s, 1H), 8.16 (s, 1H), 8.14 (s, 1H), 7.99 (d, J = 7.7 
Hz, 2H), 7.85 (d, J = 8.3 Hz, 2H), 7.53 (d, J = 7.6 Hz, 2H), 7.50 (d, J = 7.6 Hz, 2H), 7.43 
(t, J = 7.1 Hz, 2H), 7.38 (t, J = 6.4 Hz, 1H), 7.29 (t, J = 7.2 Hz, 2H), 7.22 (d, J = 6.8 Hz, 




149.9, 148.6, 142.8, 140.2, 138.4, 136.6, 136.1, 135.4, 134.0, 133.9, 133.6, 133.4, 133.1, 
132.3, 131.8, 130.6, 130.5, 57.4, 50.8; HRMS (ESI): m/z, calcd. for C28H24N5O2 [M+H]
+ 
461.1925, found 461.1901. 
 
Methyl (E)-3-(4-(4,5-diphenyl-1H-imidazol-2-yl)phenyl)-2-((4-nitro-1H-
imidazol-1-yl)methyl) acrylate (9c ): Yield: 85%; yellow solid; mp: 235 – 237 °C; 1H 
NMR (400 MHz, DMSO-d6): δ 12.83 (s, 1H), 8.27 (s, 1H), 8.15 (d, J = 8.0 Hz, 2H), 8.03 
(s, 1H), 7.84 (s, 1H), 7.60 (d, J = 8.2 Hz, 2H), 7.56 – 7.24 (m, 10H), 5.20 (s, 2H), 3.74 (s, 
3H); 13C NMR (101 MHz, DMSO-d6): δ 167.1, 147.6, 145.3, 145.2, 137.9, 133.5, 132.0, 
130.9, 129.1, 128.5, 128.0, 126.1, 125.4, 121.8, 53.1, 44.9; HRMS (ESI): m/z, calcd. for 
C29H23N5NaO4 [M+Na]











1H-imidazol-1-yl)methyl)acrylate (9d): Yield: 86%; yellow solid; mp: 258 – 260 °C; 1H 




8.03 (s, 1H), 7.59 (d, J = 8.4 Hz, 2H), 7.53 (d, J = 7.1 Hz, 2H), 7.51 – 7.47 (m, 2H), 7.44 
(t, J = 7.4 Hz, 2H), 7.40 – 7.35 (m, 1H), 7.29 (t, J = 7.5 Hz, 2H), 7.21 7.24 – 7.17(m, 
1H), 5.11 (s, 2H), 3.72 (s, 3H), 2.21 (s, 3H); 13C NMR (101 MHz, DMSO-d6): δ 166.9, 
146.1, 145.9, 145.3, 144.7, 138.3, 135.5, 133.6, 131.9, 131.4, 130.7, 129.6, 129.4, 129.1, 
128.9, 128.7, 127.8, 127.4, 126.0, 125.8, 122.1, 53.1, 43.8, 13.4. HRMS (ESI): m/z, 
calcd. for C30H25N5NaO4 [M+Na]
+ 542.1799, found 528.1771. 
 
Methyl (E)-3-(4-(4,5-diphenyl-1H-imidazol-2-yl)phenyl)-2-
(morpholinomethyl)acrylate (9e): Yield: 79%; pale yellow solid; mp: 210 – 212 °C; 1H 
NMR (400 MHz, DMSO-d6): δ 12.78 (s, 1H), 8.14 (d, J = 8.4 Hz, 2H), 7.85 (d, J = 8.4 
Hz, 2H), 7.83 (s, 1H), 7.54 (d, J = 7.3 Hz, 2H), 7.50 (d, J = 7.2 Hz, 2H), 7.43 (t, J = 7.5 
Hz, 2H), 7.36 (t, J = 7.2 Hz, 1H), 7.29 (t, J = 7.7 Hz, 2H), 7.21 (t, J = 7.2 Hz, 1H), 3.75 
(s, 3H), 3.56 (m, 4H), 3.32 (s, 2H), 2.40 (m, 4H); 13C NMR (101 MHz, DMSO-d6): δ 
168.8, 145.6, 143.1, 138.3, 135.7, 135.1, 131.8, 131.6, 131.5, 129.4, 129.3, 129.1, 129.1, 
128.9, 128.5, 127.8, 127.3, 125.7, 66.9, 54.2, 53.6, 52.8. HRMS (ESI): m/z, calcd. for 
C30H30N3O3 [M+H]






imidazol-2-yl)phenyl)acrylate (9f ): Yield: 76%; pale yellow solid; mp: 168 – 170 °C; 1H 
NMR (400 MHz, CDCl3): δ 9.45 (s, 1H), 7.96 (d, J = 7.9 Hz, 2H), 7.89 (s, 1H), 7.81 (d, J 
= 8.3 Hz, 2H), 7.67 (d, J = 6.4 Hz, 2H), 7.47 (d, J = 6.8 Hz, 2H), 7.43-7.28 (m, 6H), 3.84 
(s, 3H), 3.69-3.60 (m, 2H), 3.34 (s, 2H), 2.68 (d, J = 10.7 Hz, 2H), 1.87 (t, J = 10.8 Hz, 
2H), 1.15 (s, 3H), 1.14 (s, 3H); HRMS (ESI): m/z, calcd. for C32H34N3O3 [M+H]
+ 
508.2595, found 508.2574. 
 
Methyl (E)-3-(4-(4,5-diphenyl-1H-imidazol-2-yl)phenyl)-2-((4-methylpiperazin-
1-yl)methyl) acrylate (9g): Yield: 73%; pale yellow solid; mp: 184 – 186 °C; 1H NMR 
(400 MHz, CDCl3): δ 9.66 (s, 1H), 7.94 (d, J = 8.1 Hz, 2H), 7.87 (s, 1H), 7.79 (d, J = 8.0 
Hz, 2H), 7.66 (d, J = 7.3 Hz, 2H), 7.46 (d, J = 7.9 Hz, 2H), 7.41 – 7.27 (m, 6H), 3.82 (s, 
3H), 3.36 (s, 2H), 2.63 – 2.31 (m, 8H), 2.26 (s, 3H); 13C NMR (101 MHz, DMSO-d6): δ 




129.1, 129.1, 128.9, 128.9, 127.8, 127.8, 127.3, 125.7, 55.4, 53.7, 52.8, 52.7, 46.3; 
HRMS (ESI): m/z, calcd. for C31H33N4O2 [M+H]
+ 493.2598, found 493.2584. 
 
Methyl (E)-2-(((2-(dimethylamino)ethyl)(methyl)amino)methyl)-3-(4-(4,5-
diphenyl-1H-imidazol-2-yl)phenyl)acrylate (9h): Yield: 76%; pale yellow solid; mp: 161 
– 163 °C; 1H NMR (400 MHz, DMSO-d6): δ 12.78 (s, 1H), 8.11 (d, J = 8.1 Hz, 2H), 7.83 
(d, J = 8.3 Hz, 2H), 7.75 (s, 1H), 7.53 (d, J = 7.5 Hz, 2H), 7.49 (d, J = 7.6 Hz, 2H), 7.44 
(m, 2H), 7.40 – 7.34 (m, 1H), 7.32 – 7.26 (m, 2H), 7.24 – 7.19 (m, 1H), 3.74 (s, 3H), 3.36 
(s, 2H), 2.46 – 2.41 (m, 2H), 2.33 (t, J = 6.7 Hz, 2H), 2.12 (s, 3H), 2.11 (s, 6H); 13C NMR 
(101 MHz, DMSO-d6): δ 169.1, 145.6, 142.1, 138.2, 135.7, 135.1, 131.8, 131.6, 131.4, 








imidazol-2-yl) phenyl)acrylate (9i): Yield: 85%; pale yellow solid; mp: 225 – 227 °C; 1H 
NMR (400 MHz, DMSO-d6): δ 12.85 (s, 1H), 8.12 (d, J = 7.8 Hz, 2H), 7.96 (s, 1H), 7.60 
– 7.56 (m, 3H), 7.51 (dd, J = 7.8, 5.7 Hz, 4H), 7.34 – 7.09 (m, 4H), 7.01 (s, 1H), 6.87 (s, 
1H), 5.05 (s, 2H), 3.74 (s, 3H); 13C NMR (101 MHz, DMSO): δ 167.45, 162.14 (d, J = 
243.9 Hz), 145.35, 143.87, 137.71, 133.91, 131.82, 130.66, 129.23, 127.16, 126.06, 
119.49, 116.15 (d, J = 21.3 Hz), 53.04, 43.27; HRMS (ESI): m/z, calcd. for 
C29H23F2N4O2 [M+H]
+ 497.1784, found 497.1755. 
 
Methyl (E)-2-((1H-1,2,4-triazol-1-yl)methyl)-3-(4-(4,5-bis(4-fluorophenyl)-1H-
imidazol-2-yl) phenyl)acrylate (9j): Yield: 83%; pale yellow solid; mp: 229 – 231 °C; 1H 
NMR (400 MHz, DMSO-d6): δ 12.84 (s, 1H), 8.58 (s, 1H), 8.13 (d, J = 7.9 Hz, 2H), 8.00 




4H), 5.23 (s, 2H), 3.71 (s, 3H); 13C NMR (101 MHz, DMSO-d6): δ 167.10, 163.34 (d, J = 
242.5 Hz), 161.23, 152.18, 145.64, 145.39, 144.08, 137.41, 133.97, 131.89, 131.31 (d, J 
= 7.0 Hz), 130.89, 129.59 (d, J = 7.6 Hz), 128.36 (d, J = 2.6 Hz), 127.83 (d, J = 3.9 Hz), 
126.07, 125.93, 116.45 (d, J = 21.3 Hz), 115.86 (d, J = 21.3 Hz), 52.92, 46.25; HRMS 
(ESI): m/z, calcd. for C28H21F2N5NaO2 [M+Na]
+ 520.1556, found 520.1535. 
 
Methyl (E)-3-(4-(4,5-bis(4-fluorophenyl)-1H-imidazol-2-yl)phenyl)-2-((4-nitro-
1H-imidazol-1-yl)methyl)acrylate (9k): Yield: 87%; pale yellow solid; mp: 225 – 227 °C; 
1H NMR (400 MHz, DMSO): δ 12.87 (s, 1H), 8.26 (s, 1H), 8.12 (d, J = 8.0 Hz, 2H), 8.03 
(s, 1H), 7.84 (s, 1H), 7.60 (d, J = 8.1 Hz, 2H), 7.55 – 7.47 (m, 4H), 7.34 – 7.25 (m, 2H), 
7.18 – 7.10 (m, 2H), 5.20 (s, 2H), 3.74 (s, 3H); 
 
Methyl (E)-3-(4-(4,5-bis(4-fluorophenyl)-1H-imidazol-2-yl)phenyl)-2-((2-methyl-




256 °C; 1H NMR (400 MHz, DMSO): δ 12.86 (s, 1H), 8.13 (d, J = 8.2 Hz, 2H), 8.06 (s, 
1H), 8.02 (s, 1H), 7.59 (d, J = 8.2 Hz, 2H), 7.57 – 7.47 (m, 4H), 7.30 (t, J = 8.8 Hz, 2H), 
7.14 (t, J = 8.7 Hz, 2H), 5.11 (s, 2H), 3.72 (s, 3H), 2.21 (s, 3H); 13C NMR (101 MHz, 
DMSO): δ 166.85, 162.34 (d, J = 242.2 Hz), 161.32, 145.99, 145.30, 144.63, 137.46, 
133.73, 131.91, 131.34 (d, J = 8.9 Hz), 130.78, 129.57 (d, J = 5.2 Hz), 125.99, 125.85, 
122.14, 116.46 (d, J = 17.6 Hz), 115.86 (d, J = 21.3 Hz), 53.05, 43.88, 13.45. 
 
Methyl (E)-3-(4-(4,5-bis(4-fluorophenyl)-1H-imidazol-2-yl)phenyl)-2-
(morpholinomethyl) acrylate (9m): Yield: 74%; pale yellow solid; mp: 224 – 226 °C; 1H 
NMR (400 MHz, DMSO): δ 12.81 (s, 1H), 8.12 (d, J = 8.2 Hz, 2H), 7.85 (d, J = 8.4 Hz, 
2H), 7.82 (s, 1H), 7.56 – 7.48 (m, 4H), 7.29 (t, J = 8.7 Hz, 2H), 7.14 (t, J = 8.8 Hz, 2H), 
3.75 (s, 3H), 3.56 (m, 4H), 3.31 (s, 2H), 2.42-2.36 (m, 4H); HRMS (ESI): m/z, calcd. for 
C30H27F2N3NaO3 [M+Na]
+ 538.1913, found 538.1894. 13C NMR (101 MHz, DMSO): δ 
168.6, 162.14 (d, J = 246.5 Hz), 161.57 (d, J = 248.2 Hz), 145.4, 142.8, 134.9, 131.6, 
131.1, 130.96 (d, J = 7.6 Hz), 129.36 (d, J = 8.0 Hz), 129.1, 125.5, 116.14 (d, J = 24.6 






2,6-dimethyl morpholino)methyl)acrylate (9n): Yield: 75%; pale yellow solid; mp: 118 – 
120 °C; 1H NMR (400 MHz, DMSO): δ 12.80 (s, 1H), 8.11 (d, J = 7.6 Hz, 2H), 7.85 (d, J 
= 7.9 Hz, 2H), 7.82 (s, 1H), 7.57-7.44 (m, 4H), 7.29 (t, J = 8.5 Hz, 2H), 7.14 (t, J = 8.2 
Hz, 2H), 3.74 (s, 3H), 3.58 – 3.44 (m, 2H), 3.28 (s, 1H), 2.68-2.60 (m, 2H), 1.71 (t, J = 
10.3 Hz, 3H), 1.03 (s, 3H), 1.02 (s, 3H); HRMS (ESI): m/z, calcd. for C32H31F2N3NaO3 
[M+Na]+ 566.2226, found 566.2210. 
 
Methyl (E)-3-(4-(4,5-bis(4-fluorophenyl)-1H-imidazol-2-yl)phenyl)-2-((4-
methylpiperazin-1-yl) methyl)acrylate (9o): Yield: 72%; yellow solid; mp: 204 – 206 °C; 
1H NMR (400 MHz, DMSO): δ 12.81 (s, 1H), 8.11 (d, J = 8.0 Hz, 2H), 7.86 (d, J = 8.2 
Hz, 2H), 7.80 (s, 1H), 7.59 – 7.46 (M, 4H), 7.36 – 7.25 (m, 2H), 7.19 – 7.10 (m, 2H), 









(dimethylamino) ethyl)(methyl)amino)methyl)acrylate (9p): Yield: 76%; pale yellow 
solid; mp: 81 – 83 °C; 1H NMR (400 MHz, DMSO-d6): δ 12.81 (s, 1H), 8.09 (d, J = 7.3 
Hz, 2H), 7.83 (d, J = 7.7 Hz, 2H), 7.75 (s, 1H), 7.56 – 7.48 (m, 4H), 7.33 – 7.10 (m, 4H), 
3.74 (s, 3H), 3.34 (s, 2H), 2.43 (t, J = 6.3 Hz, 2H), 2.33 (t, J = 6.6 Hz, 2H), 2.12 (s, 3H), 
2.11 (s, 6H). 
General procedure for the synthesis of quaternary ammonium salts. To a 
stirred solution of appropriate tertiary amine (1 mmol), was added alkyl halide (1.3 
mmol) in tetrahydrofuran (5 mL), and stirred for overnight to affect the precipitation. 
Then filtered the solid and the resulting the solid was purified by triturating with diethyl 







dimethyl piperazin-1-ium iodide (10a): Yield: 89%; pale cream solid; mp: 205 – 207 °C; 
1H NMR (400 MHz, DMSO-d6): δ 12.81 (s, 1H), 8.17 (d, J = 8.3 Hz, 2H), 7.88 (s, 1H), 
7.80 (d, J = 8.3 Hz, 2H), 7.53 (d, J = 7.3 Hz, 2H), 7.49 (d, J = 7.2 Hz, 2H), 7.44 (t, J = 
7.4 Hz, 2H), 7.38 (t, J = 7.3 Hz, 1H), 7.30 (t, J = 7.5 Hz, 2H), 7.22 (t, J = 7.3 Hz, 1H), 
3.77 (s, 3H), 3.47 (s, 2H), 3.41 (s, 4H), 3.11 (s, 6H), 2.78 (s, 4H); 13C NMR (101 MHz, 
DMSO-d6): δ 168.7, 145.5, 143.7, 138.2, 135.7, 134.8, 131.9, 131.6, 131.5, 129.5, 129.4, 
129.1, 128.9, 128.8, 127.7, 127.3, 125.9, 61.4, 52.9, 52.6, 46.3. 
 
(E)-4-(3-(4-(4,5-diphenyl-1H-imidazol-2-yl)phenyl)-2-(methoxycarbonyl)allyl)-1-(2-
(methoxy carbonyl)allyl)-1-methylpiperazin-1-ium bromide (10b): Yield: 81%; yellow 
solid; mp: 140 – 142 °C; 1H NMR (400 MHz, DMSO-d6): δ 8.22 (d, J = 8.5 Hz, 2H), 
7.93 – 7.86 (m, 3H), 7.56 – 7.50 (m, 4H), 7.49 – 7.39 (m, 6H), 6.81 (s, 1H), 6.47 (s, 1H), 








amino)-N,N,N-trimethylethan-1-aminium iodide (10g): Yield: 86%; pale yellow solid; 
mp: 203 – 205 °C; 1H NMR (400 MHz, DMSO-d6): δ 12.79 (s, 1H), 8.14 (d, J = 8.2 Hz, 
2H), 7.78 (s, 1H), 7.68 (d, J = 8.3 Hz, 2H), 7.53 (d, J = 7.4 Hz, 2H), 7.49 (d, J = 7.1 Hz, 
2H), 7.44 (t, J = 7.5 Hz, 2H), 7.40 – 7.35 (m, 1H), 7.30 (t, J = 7.5 Hz, 2H), 7.22 (t, J = 
7.2 Hz, 1H), 3.76 (s, 3H), 3.49 (s, 2H), 3.44 (t, J = 5.8 Hz, 2H), 3.03 (s, 9H), 2.76 (s, 2H), 
2.13 (s, 3H); 13C NMR (101 MHz, DMSO-d6): δ 168.9, 145.5, 141.9, 138.2, 135.7, 134.8, 
131.5, 131.4, 131.3, 130.3, 129.5, 129.4, 129.1, 128.9, 128.6, 127.8, 127.3, 125.8, 61.9, 


















2-en-1-aminium bromide (10h): Yield: 79%; pale yellow solid; mp: 87 – 89 °C; 1H NMR 
(400 MHz, DMSO-d6): δ 8.22 (d, J = 8.5 Hz, 2H), 7.92 – 7.84 (m, 3H), 7.53 (d, J = 6.7 
Hz, 4H), 7.49 – 7.38 (m, 6H), 6.81 (s, 1H), 6.47 (s, 1H), 4.35 (s, 2H), 3.78 (s, 3H), 3.74 
(s, 3H), 3.57 – 3.36 (m, 10H), 2.98 (s, 3H), 2.82 – 2.74 (m, 2H); 13C NMR (101 MHz, 
DMSO-d6): δ 168.9, 145.5, 142.0, 138.2, 135.7, 134.8, 131.4, 131.3, 130.3, 129.5, 129.4, 




(methoxycarbonyl)allyl)-1,1-dimethylpiperazin-1-ium iodide (10d): Yield: 86%; pale 
yellow solid; mp: 256 – 258 °C; 1H NMR (400 MHz, DMSO-d6): δ 12.84 (s, 1H), 8.15 
(d, J = 6.5 Hz, 2H), 7.87 (d, J = 2.2 Hz, 1H), 7.80 (d, J = 6.6 Hz, 2H), 7.56 – 7.48 (m, 
4H), 7.31 (t, J = 8.8 Hz, 2H), 7.15 (t, J = 8.9 Hz, 2H), 3.77 (s, 3H), 3.46 (s, 2H), 3.41 (m, 
4H), 3.11 (s, 6H), 2.77 (m, 4H); 13C NMR (101 MHz, DMSO) δ. 13C NMR (101 MHz, 
DMSO) δ 168.72, 162.39 (d, J = 253.0 Hz), 145.57, 143.65, 137.35, 134.91, 131.88, 
131.41, 131.27 (d, J = 6.3 Hz), 129.60, 129.58 (d, J = 11.0 Hz), 128.82, 128.34 (d, J = 







(10e ): Yield: 82%; pale yellow solid; mp: 130 – 132 °C; 1H NMR (400 MHz, DMSO-
d6): δ 12.92 (s, 1H), 8.16 (d, J = 7.3 Hz, 2H), 7.87 (s, 1H), 7.80 (d, J = 8.0 Hz, 2H), 7.57 
– 7.47 (m, 4H), 7.36 – 7.10 (m, 4H), 6.80 (s, 1H), 6.47 (s, 1H), 4.34 (s, 2H), 3.76 (s, 3H), 
3.75 (s, 3H), 3.47 (s, 2H), 3.45 – 3.36 (m, 4H), 2.98 (s, 3H), 2.91 – 2.70 (m, 4H); 13C 
NMR (101 MHz, DMSO) δ 168.69, 166.32, 162.15 (d, J = 244.1 Hz), 145.53, 143.65, 
141.72, 134.96, 131.88, 131.32, 130.70 (d, J = 7.8 Hz), 130.52 (d, J = 14.0 Hz), 129.03, 








(10j): Yield: 82%; yellow solid; mp: 138 – 140 °C; 1H NMR (400 MHz, DMSO): δ 12.82 
(s, 1H), 8.11 (d, J = 8.2 Hz, 2H), 7.77 (s, 1H), 7.68 (d, J = 8.2 Hz, 2H), 7.55 – 7.47 (m, 
4H), 7.30 (t, J = 8.7 Hz, 2H), 7.15 (t, J = 8.8 Hz, 2H), 3.76 (s, 3H), 3.48 (s, 2H), 3.44 (t, J 
= 5.8 Hz, 2H), 3.03 (s, 9H), 2.79 – 2.71 (m, 2H), 2.12 (s, 3H); 13C NMR (101 MHz, 
DMSO): δ 168.90, 161.79 (d, J = 242.4 Hz), 145.51, 141.91, 137.35, 134.87, 131.98, 
131.95, 131.35, 131.29, 129.58 (d, J = 7.2 Hz), 127.81 (d, J = 2.5 Hz), 125.83, 116.48 (d, 
J = 22.0 Hz), 115.88 (d, J = 20.8 Hz), 61.95, 53.63, 53.26, 52.89, 51.61, 41.21; 
 
(E)-N-(2-((3-(4-(4,5-Bis(4-fluorophenyl)-1H-imidazol-2-yl)phenyl)-2-
(methoxycarbonyl) allyl) (methyl)amino)ethyl)-N,N-dimethylprop-2-en-1-aminium 
bromide (10l): Yield: 77%; yellow solid; Mp: 128 – 130 °C; 1H NMR (400 MHz, 
DMSO): δ 12.84 (s, 1H), 8.12 (d, J = 8.0 Hz, 2H), 7.77 (s, 1H), 7.68 (d, J = 8.0 Hz, 2H), 
7.56 – 7.46 (m, 4H), 7.30 (t, J = 8.5 Hz, 2H), 7.15 (t, J = 8.2 Hz, 2H), 6.08 – 5.93 (m, 
1H), 5.63 – 5.50 (m, 2H), 3.94 (d, J = 6.4 Hz, 2H), 3.75 (s, 3H), 3.48 (s, 2H), 3.43 – 3.36 
(m, 2H), 2.98 (s, 6H), 2.82 – 2.72 (m, 2H), 2.13 (s, 3H); 13C NMR (101 MHz, DMSO): δ 
168.90, 145.52, 141.96, 137.34, 134.85, 132.01, 131.37, 131.30, 130.35, 129.60 (d, J = 
8.1 Hz), 128.30 (d, J = 2.1 Hz), 128.03 (d, J = 2.1 Hz), 126.69, 125.87, 116.44 (d, J = 
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